Open AccessPrognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non‐small‐cell lung cancer
Author(s) -
Harada Hiroaki,
Miyamoto Kazuaki,
Yamashita Yoshinori,
Taniyama Kiyomi,
Mihara Kazuko,
Nishimura Mitsuki,
Okada Morihito
Publication year - 2015
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.507
Subject(s) - methylation , lung cancer , pathological , stage (stratigraphy) , oncology , biomarker , adenocarcinoma , hazard ratio , medicine , proportional hazards model , adjuvant therapy , cancer , cancer research , biology , gene , genetics , paleontology , confidence interval
Although curative resection is the current treatment of choice for localized non‐small‐cell lung cancer ( NSCLC ), patients show a wide spectrum of survival even after complete resection of pathological stage I NSCLC . Thus, identifying molecular biomarkers that help to accurately select patients at high risk of relapse is an important key to improving the treatment strategy. The purpose of this study was to evaluate the prognostic signature of protocadherin 10 ( PCDH 10 ) promoter methylation in curatively resected pathological stage I NSCLC . Using methylation‐specific polymerase chain reaction assays, methylation of PCDH 10 promoter was assessed in cancer tissues of 109 patients who underwent curative resection of pathological stage I NSCLC . Associations between PCDH 10 methylation status and disease outcome was analyzed. PCDH 10 promoter methylation was detected in 46/109 patients (42.2%). Patients with methylated PCDH 10 showed significantly worse recurrence‐free, overall, and disease‐specific survival compared with those without methylation ( P < 0.0001, P = 0.0004, P = 0.0002, respectively). Multivariate Cox proportional hazard regression analysis revealed that adjusted hazard ratios of methylated PCDH 10 were 5.159 for recurrence‐free, 1.817 for overall, and 5.478 for disease‐specific survival ( P = 0.0005, P = 0.1475, P = 0.0109, respectively). The pattern of recurrence was not significantly different between patients with and without PCDH 10 methylation ( P = 0.5074). PCDH 10 methylation is a potential biomarker that predicts a poor prognosis after curative resection of pathological stage I NSCLC . Assessment of PCDH 10 methylation status might assist in patient stratification for determining an appropriate adjuvant treatment and follow‐up strategy.